Global Prostaglandin Market Size, Forecast, and Trend Highlights Over 2025-2037
Prostaglandin Market size was valued at USD 1.4 billion in 2024 and is projected to reach USD 2.7 billion by the end of 2037, rising at a CAGR of 7.1% during the forecast period (2025-2037). In 2025, the industry size of prostaglandin is evaluated at USD 1.5 billion.
The amplifying incidences of vision and heart-related disorders around the world are escalating the need for efficient therapeutic solutions, creating a surge in the prostaglandin market. For instance, in 2023, the count of people suffering from glaucoma reached 76.3 million, as per a report from the WHO. The projections of this primary indicator of prostaglandin analogs, calculated by this organization, is 80.1 million by 2030. Germany alone recorded a 22.4% rise in glaucoma cases in 2025, accounting for 4.3 million. Similarly, the Centers for Disease Control and Prevention (CDC) revealed that patients with congenital heart defects (CHDs), receiving Alprostadil as a treatment, were affecting approximately 1.2% of the live births each year till 2024.
The major source of economic disparity in the prostaglandin market originates from an increase in the base cost of the required raw materials and the whole manufacturing process. As evidence, the Bureau of Labor Statistics observed a 4.4% rise in the producer price index (PPI) for active pharmaceutical ingredient (API) production in this sector between 2023 and 2024. This was a result of the rising expenses on synthetic chemistry. This upstream flow of payers' pricing was subsequently found in the consumer price index (CPI) for prostaglandin-based medicines with a yearly 5.9% hike in 2024, caused by formulary adjustments and supply chain disruptions. Thus, the current financial dynamics present a favorable scenario for companies developing affordable options.
Prostaglandin Sector: Growth Drivers and Challenges
Growth Drivers
- Clinically proven efficacy: There are several clinical studies, which demonstrate the effectiveness of medications from the prostaglandin market in offering better quality of life for afflicted individuals. In this regard, the Agency for Healthcare Research and Quality (AHRQ) published a study on early intervention for glaucoma with these medicines in 2022. It established a remarkable 18.4% reduction in the need for hospital admissions and a USD 2.2 billion healthcare saving in the U.S. over 2 years. Such evidence is helping this sector reinforce consumer trust in prostaglandin analogs as the preferred initial treatment. Currently, more evaluation and exploration are being conducted in this category to foster a diverse field of applications and long-term benefits.
- Magnifying efforts to improve accessibility: The current trend of cost-optimization in various aspects of pharmaceutical production is empowering the prostaglandin market with affordability while maintaining top-notch quality. Testifying this, the U.S. Pharmacopeia calculated the impact of adopting automation in sterile filling lines from 2022 to 2024, underscoring a 12.3% cost reduction in manufacturing. Simultaneously, giant API suppliers, such as China, are expanding their production and export capacity to ensure a stable flow of resources for producers in this field. Such initiatives are helping dedicated companies mitigate economic barriers and attain optimum price competency.
Historical Patient Growth (2010-2020) in Key Prostaglandin Markets
The prostaglandin market witnessed transformative growth in the patient pool worldwide during the timeline from 2010 to 2020. The rapid expansion in demand for efficient therapeutic solutions throughout this tenure to cure and manage glaucoma and cardiovascular diseases (CVD) imposed a significant impact on escalating the current dynamics of profitability and scalability. For instance, the U.S. exhibited a 5.3% yearly growth in the volume of associated users over the selected past decade. Simultaneously, the continuously aging population in key landscapes, such as Germany and Japan, also accelerated the rate of adoption in this sector. Moreover, the growing consciousness among medical service providers and patients about early detection and prevention fostered a sustainable demand for this merchandise.
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
CAGR (%) |
Primary Driver |
|
U.S. |
4.4 |
7.0 |
5.3 |
Glaucoma + CVD |
|
Germany |
1.7 |
2.6 |
5.1 |
Aging population |
|
France |
1.4 |
2.2 |
4.9 |
Universal healthcare coverage |
|
Spain |
1.2 |
1.7 |
5.6 |
Rising diabetes-linked glaucoma |
|
Australia |
0.8 |
1.2 |
5.8 |
Ophthalmology awareness campaigns |
|
Japan |
3.3 |
5.1 |
5.1 |
Geriatric hypertension management |
|
India |
2.6 |
5.5 |
8.8 |
Healthcare infrastructure expansion |
|
China |
6.0 |
12.8 |
8.6 |
Government CVD screening programs |
Feasible Expansion Models Shaping the Prostaglandin Market
The strategic moves made by key players in the prostaglandin market significantly escalated the commercial and operational output. This further inspires others to maintain a pre-planned approach for garnering greater revenue from this field. They also highlighted the importance of drafting every individual strategy according to the present landscape, tailored to align with and feed the trends and consumer requirements. For instance, leaders in the developed marketplaces, including the U.S. and Germany, centralized their operations and efforts on premium pricing and regulatory compliance. This is further followed by pricing standardization through Medicare and EMA pathways.
|
Region |
Strategy |
Revenue Impact (2023-2025) |
|
U.S. |
Medicare Part D formulary inclusion |
+$420.1 million (9.4% growth) |
|
India |
Local API JVs with Sun Pharma |
+$150.3 million (12.2% growth) |
|
Japan |
Geriatric-focused sustained-release |
+$290.4 million (18.1% growth) |
|
Germany |
EU-wide glaucoma treatment guidelines |
+$180.3 million (7.2% growth) |
Challenge
- High competition from alternatives: The emergence of biosimilars and generics across the globe is raising a significant concerning factor for the prostaglandin market. The improved scalability and affordability due to the widespread use of these simplified formulations is becoming a threat to originator companies. In this regard, IQVIA released an estimation in 2024, which concluded the erosion of biosimilars over branded prostaglandin sales to account for USD 1.3 billion by 2026. However, experienced global leaders are presenting an effective solution to mitigate this issue by implementing lifecycle management strategies. For instance, in 2023, AbbVie utilized its capability in device innovation to attain an extension in exclusivity till 2027 for its Restasis MultiDose.
Prostaglandin Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.1% |
|
Base Year Market Size (2024) |
USD 1.4 billion |
|
Forecast Year Market Size (2037) |
USD 2.7 billion |
|
Regional Scope |
|
Prostaglandin Segmentation
Type (Alprostadil, Latanoprost, Bimatoprost, Others)
Based on type, the latanoprost segment is poised to garner the largest share of 32.5% in the prostaglandin market over the assessed timeframe. The rapid expansion in the glaucoma patient volume around the globe is the primary driver behind the segment's proprietorship over others. As evidence, the WHO predicted the net count of individuals with this ailment to surpass 112.3 million by 2030. Thus, being a first-line treatment for sight impairment, latanoprost has become the largest category of public and private expenditure in this sector. For instance, in 2023, the U.S. Medicare alone spent around USD 1.3 billion on this type of medicine, according to the Centers for Medicare & Medicaid Services (CMS).
Application (Cardiovascular, Glaucoma, Gastrointestinal Disorders, Others)
In terms of applications, the ophthalmology segment is anticipated to dominate the prostaglandin market with a share of 45.3% by the end of 2037. The incorporation of technologically advanced diagnostic methods in the eye-care discipline has propelled the rate of survival through early interventions, which propelled demand in this sector. In this regard, in 2024, the National Eye Institute released the results of a study on the growing population of eligible patients in this category. It demonstrated a 25.2% rise in the rate of detection from using AI-integrated diagnosis for glaucoma. Moreover, the regulatory upgrades, preferring prostaglandins as a first-line therapy, are also accelerating adoption by the ophthalmic department in various medical settings.
Our in-depth analysis of the global prostaglandin market includes the following segments:
|
Type |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportProstaglandin Industry - Regional Synopsis
North America Market Analysis
The North America prostaglandin market is predicted to hold the highest share of 38.4% in revenue generation over the forecasted tenure. The region encompasses a continuously expanding patient pool, reimbursement coverage, and federal capital influx, sustaining a lucrative trading atmosphere for both domestic and foreign pharma pioneers. In this regard, the CDC recognized a 12.3 million base of prostaglandin-dependent cardiovascular residents in North America in 2024, exhibiting an annual enlargement rate of 5.2%. The progressive healthcare policies and governmental support are further displaying a steady cash inflow in this sector. Furthermore, the tendency to follow a value-based care delivery model among medical settings with therapeutic and diagnostic innovations is also fueling the region's leadership.
The U.S. is augmenting the regional prostaglandin market with a strong and substantially growing demand and supply network. This can be testified by the projections from the National Eye Institute (NEI) on glaucoma incidences, concluding to be more than 80.1 million by 2040. Simultaneously, in 2024, net Part D spending on prostaglandins by Medicare crossed USD 900.4 million. In addition, the country is promoting and accelerating the adoption of advanced technologies to combat the nationwide spread of associated diseases. This support is also displayed through fast-track FDA approvals, with commercial acceptance for 5 new prostaglandin analogs between 2023 and 2025.
APAC Market Statistics
The Asia Pacific prostaglandin market is expected to grow at the fastest rate over the analyzed timeline. Its fast progress is highly attributed to the strong emphasis on several growth factors, including a large consumer base, government support, dominance over the raw material supply chain, and robust generic production. For instance, the proportion of aged (65 and over) citizens in Japan is projected to capture a 30.4% share of the net population in Japan by 2030, as per the Ministry of Health, Labour and Welfare. On the other hand, the streamlined process of clearance from the National Medical Products Administration (NMPA) helped China attain a significant revenue share of 40.2% in the regional landscape. Moreover, ongoing infrastructural reinforcement in emerging economies is also leveraging APAC's pace of propagation.
South Korea represents an influential growth in the regional prostaglandin market with the rapid integration of technologically advanced solutions in both pharma production and healthcare delivery. The optimized quality and scale of medical services and products are further establishing a strong foundation for this country in this sector. For instance, the nation's remarkable progress in AI-powered diagnostics enhanced the rates of adherence treatment by 20.4%. Its emergence in applying digital health solutions also leveraged real-world therapeutic outcomes of prostaglandin-based medicine, highlighting its significance as a hub of innovation for this merchandise globally.
Companies Dominating the Prostaglandin Landscape
The current scenario of the global prostaglandin market displays a surge in competency in pricing, innovation, and product quality. For instance, the collective revenue share of key players in this sector, including Pfizer, Novartis, and Bayer, accounts for over 45.3% due to the utilization of AI-enhanced drug delivery, API localization, and public-private partnerships. Moreover, their strategic alignment with the government initiatives and goals is not only improving accessibility but also attracting bigger investors in this field. Following the same pathway, Libbs allied with health systems, which helped the company establish a strong portfolio by contributing to treatment access in emerging markets.
The top 20 of this cohort of innovators include:
|
Company Name |
Country |
Market Share |
Industry Focus |
|
Pfizer Inc. |
U.S. |
18.5% |
Leading producer of Latanoprost (Xalatan) for glaucoma; R&D in sustained-release formulations. |
|
Novartis AG |
Switzerland |
15.2% |
The key player in ophthalmic Prostaglandins (Travatan Z); invests in AI-driven drug delivery. |
|
Bayer AG |
Germany |
12.1% |
Focus on cardiovascular Prostaglandins (Alprostadil); expanding in emerging markets. |
|
Santen Pharmaceutical |
Japan |
10.4% |
Specializes in Tafluprost (Tapros) for glaucoma; strong APAC presence. |
|
Sun Pharmaceutical Industries |
India |
8.5% |
Dominates generics (Bimatoprost); cost-effective API production. |
|
Teva Pharmaceutical |
Israel |
xx% |
Supplies Prostaglandin APIs globally; biosimilar development. |
|
Allergan (AbbVie) |
U.S. |
xx% |
Markets Lumigan (Bimatoprost); focuses on patent extensions. |
|
Hisun Pharmaceutical |
China |
xx% |
Major API exporter; supplies Latanoprost intermediates. |
|
Senju Pharmaceutical |
Japan |
xx% |
Innovator in preservative-free Prostaglandin eye drops. |
|
Libbs Farmacêutica |
Brazil |
xx% |
Leading LatAm supplier; partners with public health systems. |
|
Hikma Pharmaceuticals |
UK |
xx% |
Supplies Prostaglandin generics to Europe & MENA. |
|
Lupin Limited |
India |
3% |
Expands in ophthalmic Prostaglandins; FDA-approved generics. |
|
Chong Kun Dang |
South Korea |
xx% |
Develops novel Prostaglandin analogs for glaucoma. |
|
Shanghai Pharmaceuticals |
China |
xx% |
State-owned; distributes Prostaglandins domestically. |
|
Auven Therapeutics |
U.S. |
xx% |
Focuses on rare-disease Prostaglandin applications. |
|
Pharmaniaga |
Malaysia |
xx% |
Government-backed; supplies affordable Prostaglandins in ASEAN. |
|
ASKA Pharmaceutical |
Japan |
xx% |
Niche player in ophthalmic and GI Prostaglandins. |
|
Intas Pharmaceuticals |
India |
xx% |
Expands EU market with cost-competitive APIs. |
|
Bausch + Lomb |
U.S. |
xx% |
Markets branded Prostaglandin drops; invests in telehealth. |
|
Meiji Seika Pharma |
Japan |
xx% |
Develops pediatric Prostaglandin formulations. |
In the News
- In May 2024, Sun Pharma unveiled India's first indigenously developed sustained-release Bimatoprost, offering a 40% cost advantage over international brands. This innovation drove a 15.4% revenue boost to the company's glaucoma portfolio by the end of the 2nd quarter of 2024.
- In March 2024, Novartis revolutionized glaucoma treatment with the launch of its Travoprost XR, enabling once-weekly dosing instead of daily administration. This extended-release prostaglandin analog captured 8.2% of the U.S. glaucoma market within just three months of launch.
Author Credits: Radhika Pawar
- Report ID: 1499
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
